Organogenesis Holdings is a Canton regenerative-medicine company whose wound-care franchise just collided with a Medicare payment redesign that ended spread pricing in skin substitutes. The second-quarter print is the first full look at life after that reset, and it shows a franchise that is smaller, less profitable, and still searching for a new equilibrium. Management argues that clinicians are migrating toward evidence-backed grafts such as Apligraf as weaker products leave the category. The equity debate is whether that share shift can rebuild an economic model on a flat national rate, or whether the company is now a cash-burning option on a knee-osteoarthritis biologic that does not produce revenue until a later review cycle.
Net product sales fell by more than half versus the year-ago quarter as Advanced Wound Care bore almost the entire decline. Sequential sales did rise, and wound-care unit volume improved, which is the first evidence that utilization is not still collapsing. Gross margin compressed sharply because a fixed manufacturing base now sits under a much smaller revenue pool. Cash also fell by about half from year-end, even with no bank debt on the balance sheet. That combination is the tension inside the print: share and volume are stabilizing, but the dollar economics of each graft are not what they were under the old average-sales-price regime.
Management cut full-year sales guidance to a band that implies another deep year-over-year decline and a slower second-half recovery than the prior outlook assumed. The same update still points to a fourth-quarter return to positive adjusted EBITDA after two restructuring waves. A new at-the-market equity facility sits over that plan, and a convertible preferred layer from Avista still votes and accretes above common. The open question is whether sequential volume gains can outrun cash burn and dilution before the ReNu review date.